Angela Devine1,2, Alice Vahanian3, Bernard Sawadogo4, Souleymane Zan5, Fadima Yaya Bocoum6, Helen Kelly3, Clare Gilham3, Nicolas Nagot7, Jason J Ong3,8, Rosa Legood3, Nicolas Meda4, Alec Miners3, Philippe Mayaud3. 1. Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia. 2. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Victoria, Australia. 3. London School of Hygiene & Tropical Medicine, London, United Kingdom. 4. Centre de Recherche Internationale pour la Santé, Université de Ouagadougou, Ouagadougou, Burkina Faso. 5. Centre Hospitalier Universitaire Yalgado Ouédraogo, Ouagadougou, Burkina Faso. 6. Institut de Recherche en Sciences de la Santé, Ouagadougou, Burkina Faso. 7. Pathogenesis and control of chronic infections, INSERM, Etablissement Francais du Sang, University of Montpellier, Montpellier, France. 8. Central Clinical School, Monash University, Melbourne, Victoria, Australia.
Abstract
INTRODUCTION: This study estimated the costs and incremental cost per case detected of screening strategies for high-grade cervical intraepithelial neoplasia (CIN2+) in women living with HIV (WLHIV) attending HIV clinics in Burkina Faso. METHODS: The direct healthcare provider costs of screening tests (visual inspection with acetic acid (VIA), VIA combined visual inspection with Lugol's iodine (VIA/VILI), cytology and a rapid HPV DNA test (careHPV)) and confirmatory tests (colposcopy, directed biopsy and systematic four-quadrant (4Q) biopsy) were collected alongside the HPV in Africa Research Partnership (HARP) study. A model was developed for a hypothetical cohort of 1000 WLHIV using data on CIN2+ prevalence and the sensitivity of the screening tests. Costs are reported in USD (2019). RESULTS: The study enrolled 554 WLHIV with median age 36 years (inter-quartile range, 31-41) and CIN2+ prevalence of 5.8%. The average cost per screening test ranged from US$3.2 for VIA to US$24.8 for cytology. Compared to VIA alone, the incremental cost per CIN2+ case detected was US$48 for VIA/VILI and US$814 for careHPV. Despite higher costs, careHPV was more sensitive for CIN2+ cases detected compared to VIA/VILI (97% and 56%, respectively). The cost of colposcopy was US$6.6 per person while directed biopsy was US$33.0 and 4Q biopsy was US$48.0. CONCLUSION: Depending on the willingness to pay for the detection of a case of cervical cancer, decision makers in Burkina Faso can consider a variety of cervical cancer screening strategies for WLHIV. While careHPV is more costly, it has the potential to be cost-effective depending on the willingness to pay threshold. Future research should explore the lifetime costs and benefits of cervical cancer screening to enable comparisons with interventions for other diseases.
INTRODUCTION: This study estimated the costs and incremental cost per case detected of screening strategies for high-grade cervical intraepithelial neoplasia (CIN2+) in women living with HIV (WLHIV) attending HIV clinics in Burkina Faso. METHODS: The direct healthcare provider costs of screening tests (visual inspection with acetic acid (VIA), VIA combined visual inspection with Lugol's iodine (VIA/VILI), cytology and a rapid HPV DNA test (careHPV)) and confirmatory tests (colposcopy, directed biopsy and systematic four-quadrant (4Q) biopsy) were collected alongside the HPV in Africa Research Partnership (HARP) study. A model was developed for a hypothetical cohort of 1000 WLHIV using data on CIN2+ prevalence and the sensitivity of the screening tests. Costs are reported in USD (2019). RESULTS: The study enrolled 554 WLHIV with median age 36 years (inter-quartile range, 31-41) and CIN2+ prevalence of 5.8%. The average cost per screening test ranged from US$3.2 for VIA to US$24.8 for cytology. Compared to VIA alone, the incremental cost per CIN2+ case detected was US$48 for VIA/VILI and US$814 for careHPV. Despite higher costs, careHPV was more sensitive for CIN2+ cases detected compared to VIA/VILI (97% and 56%, respectively). The cost of colposcopy was US$6.6 per person while directed biopsy was US$33.0 and 4Q biopsy was US$48.0. CONCLUSION: Depending on the willingness to pay for the detection of a case of cervical cancer, decision makers in Burkina Faso can consider a variety of cervical cancer screening strategies for WLHIV. While careHPV is more costly, it has the potential to be cost-effective depending on the willingness to pay threshold. Future research should explore the lifetime costs and benefits of cervical cancer screening to enable comparisons with interventions for other diseases.
Authors: Rosa Legood; Alastair M Gray; Cedric Mahé; Jane Wolstenholme; Kasturi Jayant; Bhagwan M Nene; Surendra S Shastri; Sylla G Malvi; Richard Muwonge; Atul M Budukh; Rengaswamy Sankaranarayanan Journal: Int J Cancer Date: 2005-12-20 Impact factor: 7.396
Authors: Richard Muwonge; Stephen D Walter; Ramani S Wesley; Partha Basu; Surendra S Shastri; Somanathan Thara; Charles Gombe Mbalawa; Rengaswamy Sankaranarayanan Journal: J Med Screen Date: 2007 Impact factor: 2.136
Authors: Sue J Goldie; Lynne Gaffikin; Jeremy D Goldhaber-Fiebert; Amparo Gordillo-Tobar; Carol Levin; Cédric Mahé; Thomas C Wright Journal: N Engl J Med Date: 2005-11-17 Impact factor: 91.245
Authors: Salomon Compaore; Charlemagne M R Ouedraogo; Seni Koanda; Gleb Haynatzki; Robert M Chamberlain; Amr S Soliman Journal: J Cancer Educ Date: 2016-12 Impact factor: 2.037